Jounce Therapeutics, Inc.
JNCENASDAQHealthcare
$1.88
+$0.00(+0.00%)
Market Cap$98954740
P/E Ratio—
52W High$5.37
52W Low$0.5773
Jounce Therapeutics, Inc. (JNCE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · JNCE · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $82.00M | $26.91M | $62.34M | $147.87M | $65.20M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $82.00M | $26.91M | $62.34M | $147.87M | $65.20M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $103.27M | $88.98M | $78.69M | $67.14M | $70.05M |
| G&A Expenses | $30.97M | $28.98M | $28.77M | $27.92M | $26.44M |
| Total Operating Expenses | $134.24M | $117.96M | $107.46M | $95.06M | $96.50M |
| Operating Income | ($52.24M) | ($91.06M) | ($45.12M) | $52.82M | ($31.29M) |
| Operating Margin %(computed) | -63.71% | -338.41% | -72.37% | 35.72% | -48.00% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($50.78M) | ($90.86M) | ($43.83M) | $56.87M | ($27.33M) |
| Income Tax Expense | $0.14M | $0.01M | $0.01M | $0.05M | $0.05M |
| Net Income | ($50.92M) | ($90.87M) | ($43.84M) | $56.82M | ($27.38M) |
| Net Margin %(computed) | -62.10% | -337.73% | -70.33% | 38.43% | -41.99% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.99 | $-1.82 | $-1.24 | $1.72 | $-0.84 |
| Wtd Avg Shares | 51.68M | 49.93M | 35.43M | 33.08M | 32.57M |
| EBITDA | ($50.16M) | ($91.06M) | ($45.12M) | $52.82M | ($23.50M) |
| EBITDA Margin %(computed) | -61.16% | -338.41% | -72.37% | 35.72% | -36.05% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Jounce Therapeutics, Inc. data
About Jounce Therapeutics, Inc. (JNCE) Income Statement
Jounce Therapeutics, Inc. (JNCE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, JNCE reported revenue of $0.08B, gross profit of $0.08B (gross margin 100.00%), and net income of ($0.05B) — a net profit margin of -62.10%.
Frequently asked questions
JNCE · 4 questionsJounce Therapeutics, Inc. (JNCE) reported revenue of $0.08B for 2022, up 204.8% year-over-year.
JNCE revenueJNCE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09